More on JNJ
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $254.66 |
|
|||
| Open | $254.66 | ||||
| 52 Wk High | $126.07 | ||||
| 52 Wk Low | $94.28 | ||||
| Day High | $254.66 | ||||
| Day Low | $254.66 | ||||
| P/E | 52.94 | ||||
| EPS | $4.81 | ||||
| Volume | 13,983 | ||||
- J&J presents new IMAAVY data for myasthenia gravis at EAN 2026
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- Johnson & Johnson (JNJ) PT Raised to $270 at Guggenheim
- Form 11-K JOHNSON & JOHNSON For: Dec 31
- Form 11-K JOHNSON & JOHNSON For: Dec 31
- Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
- Johnson & Johnson invests $1 billion in Jacksonville vision manufacturing
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
- Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination
- New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple my
Entities mentioned with JNJ
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
